The Rule That Stops Non-US Companies Before Page One
Under 21 CFR 812.18(a), a sponsor who is not a US person must designate a US person to act as the sponsor or to be the sponsor's agent for purposes of the IDE. This is not a procedural courtesy. It is a threshold requirement. FDA will not approve an IDE application that names a non-US entity as the sole responsible sponsor, and the place where that failure becomes immediately visible is the cover letter.
Why the Cover Letter Is Where This Requirement Becomes Concrete
The IDE cover letter is the first document a reviewer opens. FDA uses it to confirm jurisdiction, accountability, and point of contact before reviewing a single page of the technical file. The named sponsor field on that letter is not a label. It is a regulatory commitment. If a non-US company's name appears in the sponsor block with no US person designated, the application is structurally deficient from the first line. FDA's IDE Application Checklist states that the cover letter must identify 'the sponsor by name and address' and that information must reflect a US person or a designated US agent acting as sponsor of record. See FDA's IDE Application Checklist at https://www.fda.gov/media/77338/download. That single field is where 21 CFR 812.18(a) either passes or fails its first test.
Sponsor Block vs. Correspondent or Contact: They Are Not the Same
Many non-US companies make the same structural error. They list a US law firm, a regulatory consultant, or a US distributor in the cover letter's contact or correspondence section and assume that satisfies 21 CFR 812.18(a). It does not. A correspondent receives mail. A contact answers the phone. Neither role carries the legal obligations of a sponsor under Part 812.
The sponsor block is a separate, distinct field. It identifies the entity that owns the IDE, holds all obligations under 21 CFR Part 812, and is the party FDA holds accountable for every investigational site, every adverse event report, and every protocol deviation. A correspondent listed elsewhere on the same page does not inherit those obligations. FDA reviewers are trained to distinguish the two, and a submission that conflates them signals a misunderstanding of the regulatory framework that can delay or derail the entire review.
What Belongs in the Sponsor Block
The sponsor block on an IDE cover letter must contain three elements to be compliant and complete.
- Legal name: The full legal name of the US person or US entity acting as sponsor of record. This must match any corporate registration documents if the sponsor is a legal entity, and it must match the name that will appear throughout the IDE application body.
- US address: A physical US address, not a PO box. This address establishes US jurisdiction and is the address FDA will use for official correspondence, inspection notices, and any regulatory action letters.
- Statement of sponsor accountability: A clear, unambiguous statement that the named US sponsor accepts all obligations imposed by 21 CFR Part 812, including but not limited to responsibilities for investigator selection under 812.43, monitoring under 812.46, and recordkeeping under 812.140. This statement transforms the cover letter from an administrative form into a binding regulatory commitment.
If your device qualifies for a nonsignificant risk determination, the sponsor block carries the same requirements. A nonsignificant risk study may bypass FDA IDE approval and operate under an abbreviated IDE, but the US sponsor designation under 21 CFR 812.18(a) still applies. The rule does not relax based on risk classification.
How ADB Assesses and Prepares Your IDE Cover Letter
At ADB Consulting and CRO Inc., our regulatory team reviews every IDE submission package for US sponsor compliance before a single page goes to FDA. We assess the sponsor block against 21 CFR 812.18(a), the IDE Application Checklist, and current FDA reviewer expectations to identify gaps that would otherwise result in a refuse-to-file determination or a major deficiency letter.
For non-US device companies entering the US clinical market, ADB provides US Sponsor of Record services, accepting full Part 812 obligations on behalf of the foreign developer and ensuring that the IDE cover letter, the application body, and all site-level documentation reflect a single, compliant US sponsor identity. Learn more at adbccro.com/us-sponsor.
ADB Consulting and CRO Inc. serves as US Sponsor of Record for non-US medical device companies conducting FDA-regulated clinical investigations under 21 CFR Part 812.
Reviewed October 25, 2026 by ADB's regulatory team.
Frequently Asked Questions
Can a non-US company's US subsidiary act as the IDE sponsor?
Yes, if the subsidiary is a separately incorporated US legal entity with its own US address and its own legal capacity to accept Part 812 obligations, it may serve as the sponsor of record. The subsidiary's name, not the parent company's name, must appear in the sponsor block. ADB can review corporate structure documentation to assess whether a subsidiary qualifies under this framework.
What happens if FDA identifies a non-US entity in the sponsor block during review?
FDA will typically issue a major deficiency or a refuse-to-file determination depending on the stage of review. The sponsor will need to amend the submission, designate a compliant US sponsor, and resubmit affected sections. This adds weeks or months to the review timeline. Preparing the sponsor block correctly before submission avoids this outcome entirely.
Does the US sponsor requirement apply to expanded access or compassionate use IDE submissions?
Yes. Expanded access IDE submissions under 21 CFR 812.36 are still IDE applications governed by Part 812. The US sponsor designation requirement under 812.18(a) applies. ADB can review expanded access submissions to assess sponsor block compliance alongside the clinical and safety documentation.
Book a Free Discovery Call
If you are preparing an IDE submission or assessing whether your current sponsor structure meets FDA requirements, ADB's regulatory team is ready to review your situation and help you move forward with confidence. Visit adbccro.com to book a free discovery call with Andre Butler and the ADB team today.
Related reading: our US Sponsor of Record service covers this in more depth.
Ready to Navigate the FDA Process with Confidence?
Book a free 30-minute discovery call with ADB's regulatory team to discuss your specific device and situation.
Book a Free Pathway Call